Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | All Organs | Clear Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48 | May Have Been Related |
| Yes | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 16/50 29/50 28/50 27/50 | Neoplastic Lesions |
| Yes | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | malignant lymphoma (7/50, 17/50, 20/50, 27/50) | Neoplastic Lesions |
| Yes | TR-563 | 89-82-7 | Pulegone | Mice | B6C3F1/N | Female | Gavage | All Organs | Clear Evidence | Equivocal Evidence | Osteoma or osteosarcoma: 0/49 0/50 3/50 1/50 | May Have Been Related |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | hemangioma or hemangiosarcoma 4/50 6/50 6/50 11/50 | Neoplastic Lesions |
| Yes | TR-578 | 90045-36-6 | Ginkgo biloba extract | Rats | F344/N | Male | Gavage | All Organs | Some Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 9/50, 12/50, 22/50, 21/50 | May Have Been Related |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | All Organs | Some Evidence | Equivocal Evidence | malignant mesothelioma 0/50 1/50 1/50 0/50 | May Have Been Related |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | All Organs | Some Evidence | Some Evidence | mononuclear cell leukemia 10/50 11/50 13/50 25/50 | Neoplastic Lesions |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 28/50 23/50 | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 18/50 37/50 | Neoplastic Lesions |
| Yes | TR-587 | 79-94-7 | Tetrabromobisphenol A | Mice | B6C3F1/N | Male | Gavage | All Organs | Some Evidence | Equivocal Evidence | (Hemangiosarcoma) 1/50 5/50 8/50 | May Have Been Related |
| Yes | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | All Organs | Clear Evidence | Equivocal Evidence | Malignant Lymphoma: 2/50 5/50 8/50 7/50 | May Have Been Related |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48 | Neoplastic Lesions |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | May Have Been Related | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | May Have Been Related |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Female | Gavage | Adrenal Gland Cortex | Clear Evidence | Equivocal Evidence | Adenoma 1/50 1/50 3/50 4/49 | May Have Been Related |
| Yes | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | All Organs | Clear Evidence | Equivocal Evidence | Malignant Lymphoma: 2/50 5/50 8/50 7/50 | May Have Been Related |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | Squamous cell carcinoma 0/50 1/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | Squamous cell carcinoma 0/50 1/50 1/49 3/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | Squamous cell papilloma or carcinoma 0/50 1/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | Cholangiocarcinoma 1/50 1/50 1/49 3/49 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Male | Gavage | Liver | Clear Evidence | Clear Evidence | Cholangiocarcinoma 0/50 4/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | Lung | Clear Evidence | Clear Evidence | Alveolar/bronchiolar adenoma or carcinoma 0/49 2/50 1/50 4/50 alveolar/bronchiolar adenoma or carcinoma 3/49 8/50 5/50 10/50 cystic keratinizing epithelioma 0/49 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Male | Gavage | Lung | Clear Evidence | Clear Evidence | Alveolar/bronchiolar adenoma 5/50 16/50 12/49 6/50 alveolar/bronchiolar adenoma or carcinoma 7/50 17/50 15/49 6/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | Cystic keratinizing epithelioma 0/50 6/50 26/49 39/49 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Male | Gavage | Lung | Clear Evidence | Clear Evidence | Cystic keratinizing epithelioma 0/50 14/50 31/50 37/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | Mucosa: Gingival squamous cell carcinoma 0/50 0/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | Mucosa: Gingival squamous cell carcinoma 1/50 5/50 4/50 5/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | Skin | Clear Evidence | Clear Evidence | Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Male | Gavage | Thoracic Cavity | Clear Evidence | Equivocal Evidence | Malignant Schwannoma: 0/50 0/50 1/50 3/50 | May Have Been Related |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Rats | Harlan Sprague-Dawley | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/50 3/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | Ureter | Clear Evidence | Equivocal Evidence | Transitional epithelial carcinoma: 0/0 0/1 0/0 1/2 | May Have Been Related |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Male | Gavage | Ureter | Clear Evidence | Equivocal Evidence | Transitional epithelial carcinoma: 0/43 0/45 1/47 0/50 | May Have Been Related |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Female | Gavage | Urinary System | Clear Evidence | Clear Evidence | Urethra: Transitional epithelial gland carcinoma 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-558 | 14047-09-7 | 3,3',4,4'-Tetrachloroazobenzene | Mice | B6C3F1/N | Male | Gavage | Urinary System | Clear Evidence | Clear Evidence | Urethra: Transitional epithelial gland carcinoma 0/50 32/50 46/49 49/50 | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Rats | Wistar Han | Female | Inhalation | Adrenal Gland Medulla | Some Evidence | Some Evidence | benign pheochromocytoma (0/49, 2/49, 2/49, 6/50); benign or malignant pheochromocytoma (0/49, 2/49, 2/49, 7/50) | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Rats | Wistar Han | Male | Inhalation | Adrenal Gland Medulla | Some Evidence | Some Evidence | benign pheochromocytoma (1/49, 0/50, 2/49, 7/50) | Neoplastic Lesions |
| Yes | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | malignant lymphoma (7/50, 17/50, 20/50, 27/50) | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Rats | Wistar Han | Female | Inhalation | Lung | Some Evidence | Equivocal Evidence | cystic keratinizing epithelioma or squamous cell carcinoma (0/50, 0/50, 0/50, 3/50) | May Have Been Related |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma (1/50, 10/50, 19/50, 8/50); alveolar/bronchiolar carcinoma (2/50, 14/50, 11/50, 11/50); alveolar/bronchiolar adenoma or carcinoma (3/50, 22/50, 27/50, 18/50) | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar carcinoma (4/50, 18/50, 20/50, 27/50) | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Rats | Wistar Han | Female | Inhalation | Lung | Some Evidence | Some Evidence | alveolar/bronchiolar adenoma (0/50, 2/50, 6/50, 5/50) | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Rats | Wistar Han | Male | Inhalation | Lung | Some Evidence | Some Evidence | alveolar/bronchiolar adenoma (3/50, 4/50, 6/50, 8/50); alveolar/bronchiolar adenoma or carcinoma (3/50, 4/50, 8/50, 8/50) | Neoplastic Lesions |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Female | Inhalation | Skin | Clear Evidence | Equivocal Evidence | squamous cell carcinoma (0/50, 0/50, 0/50, 2/50) | May Have Been Related |
| No | TR-590 | 1309-64-4 | Antimony Trioxide | Mice | B6C3F1 | Male | Inhalation | Skin | Clear Evidence | Clear Evidence | fibrous histiocytoma (0/50, 1/50, 1/50, 4/50); fibrous histiocytoma or fibrosarcoma (0/50, 1/50, 3/50, 4/50) | Neoplastic Lesions |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Female | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | benign pheochromocytoma 6/50 12/50 22/50 36/50 malignant pheochromocytoma 0/50 2/50 3/50 11/50 benign or malignant pheochromocytoma 6/50 13/50 23/50 40/50 | Neoplastic Lesions |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Male | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | benign pheochromocytoma 15/50 23/50 37/50 34/50 malignant pheochromocytoma 2/50 2/50 9/50 16/50 benign or malignant pheochromocytoma 17/50 23/50 38/50 41/50 | Neoplastic Lesions |
| Yes | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 16/50 29/50 28/50 27/50 | Neoplastic Lesions |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Male | Inhalation | Kidney | Clear Evidence | Equivocal Evidence | adenoma or carcinoma (standard evaluation) 0/50 1/50 0/50 4/50 (standard and extended evaluations combined) 3/50 1/50 1/50 7/50 | May Have Been Related |
| No | TR-581 | 7440-48-4 | Cobalt | Mice | B6C3F1/N | Female | Inhalation | Lung | Clear Evidence | Equivocal Evidence | alveolar/bronchiolar adenoma 3/49 9/50 8/50 10/50 alveolar/bronchiolar carcinoma 5/49 25/50 38/50 43/50 alveolar/bronchiolar adenoma or carcinoma 8/49 30/50 41/50 45/50 | May Have Been Related |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Male | Inhalation | Lung | Clear Evidence | Equivocal Evidence | cystic keratinizing epithelioma 0/50 1/50 0/50 1/50 | May Have Been Related |
| No | TR-581 | 7440-48-4 | Cobalt | Mice | B6C3F1/N | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 7/50 11/49 15/50 3/50 alveolar/bronchiolar carcinoma 11/50 38/49 42/50 46/50 alveolar/bronchiolar adenoma or carcinoma 16/50 41/49 43/50 47/50 | Neoplastic Lesions |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 2/50 7/50 9/50 13/50 alveolar/bronchiolar carcinoma 0/50 9/50 17/50 30/50 alveolar/bronchiolar adenoma or carcinoma 2/50 15/50 20/50 38/50 cystic keratinizing epithelioma 0/50 4/50 1/50 2/50 | Neoplastic Lesions |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 2/50 10/50 10/50 14/50 alveolar/bronchiolar carcinoma 0/50 16/50 34/50 36/50 alveolar/bronchiolar adenoma or carcinoma 2/50 25/50 39/50 44/50 | Neoplastic Lesions |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Female | Inhalation | Pancreas Islet Cell | Clear Evidence | Equivocal Evidence | carcinoma 1/50 0/50 0/50 3/50 | May Have Been Related |
| No | TR-581 | 7440-48-4 | Cobalt | Rats | F344/NTac | Male | Inhalation | Pancreas Islet Cell | Clear Evidence | Clear Evidence | adenoma or carcinoma 2/50 2/50 10/48 9/49 | Neoplastic Lesions |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | May Have Been Related | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | May Have Been Related | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | POSTWEANING-ONLY STUDY (STUDY 2) | Neoplastic Lesions | |
| Yes | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | All Organs | Clear Evidence | PERINATAL AND POSTWEANING STUDY (STUDY 1) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (0/50, 0/50, 1/50, 1/50, 13/49); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 2/49); hepatocellular adenoma or carcinoma (combined) (0/50, 0/50, 1/50, 1/50, 14/49) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (1/49, 0/50, 5/50, 9/50, 5/48); hepatocellular carcinoma (0/49, 0/50, 0/50, 0/50, 8/48); hepatocellular adenoma or carcinoma (combined) (1/49, 0/50, 5/50, 9/50, 13/48) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (0/50, 2/50, 0/50, 1/50, 6/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 6/50); hepatocellular adenoma or carcinoma (combined) (0/50, 2/50, 0/50, 1/50, 12/50) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Liver | Clear Evidence | hepatocellular adenoma (0/50, 1/49, 0/50, 3/50, 8/49); hepatocellular carcinoma (1/50, 0/49, 0/50, 0/50, 3/49); hepatocellular adenoma or carcinoma (combined) (1/50, 1/49, 0/50, 3/50, 11/49) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma or carcinoma (combined) (0/50, 0/50, 0/50, 1/50, 2/47) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma or carcinoma (combined) (0/49, 0/50, 0/50, 2/50, 1/48) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma (1/49, 4/50, 5/50, 23/50, 30/50); acinar carcinoma (0/49, 1/50, 0/50, 1/50, 5/50); acinar adenoma or carcinoma (combined) (1/49, 5/50, 5/50, 23/50, 33/50) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | acinar adenoma (10/50, 7/49, 8/50, 36/50, 22/49); acinar carcinoma (0/50, 0/49, 0/50, 3/50, 1/49); acinar adenoma or carcinoma (combined) (10/50, 7/49, 8/50, 38/50, 22/49) | Neoplastic Lesions | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Male | Dosed-Feed | Testis | Clear Evidence | interstitial cell, adenoma (7/50, 3/50, 3/50, 6/50, 15/50) | May Have Been Related | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Uterus | Clear Evidence | adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (3/50, 1/50, 1/50, 3/50, 7/50) | May Have Been Related | |
| No | TR-601 | 117-81-7 | Di(2-ethylhexyl) Phthalate | Rats | Harlan Sprague-Dawley | Female | Dosed-Feed | Uterus | Clear Evidence | adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (2/50, 4/50, 1/50, 6/50, 13/50) | Neoplastic Lesions | |
| Yes | TR-578 | 90045-36-6 | Ginkgo biloba extract | Rats | F344/N | Male | Gavage | All Organs | Some Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 9/50, 12/50, 22/50, 21/50 | May Have Been Related |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Rats | F344/N | Male | Gavage | Liver | Some Evidence | Equivocal Evidence | hepatocellular adenoma 0/50, 3/50, 3/50, 0/50 | May Have Been Related |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Mice | B6C3F1/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma 17/50, 37/50, 41/50, 48/50; hepatocellular carcinoma 9/50, 10/50, 15/50, 44/50; hepatoblastoma 1/50, 1/50, 8/50, 11/50 | Neoplastic Lesions |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Mice | B6C3F1/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | hepatocellular carcinoma 22/50, 31/50, 41/50, 47/50; hepatoblastoma 3/50, 28/50, 36/50, 38/50 | Neoplastic Lesions |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Rats | F344/N | Female | Gavage | Nasal Cavity | Some Evidence | Equivocal Evidence | respiratory epithelium, adenoma 0/49, 0/49, 2/50, 0/46 | May Have Been Related |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Mice | B6C3F1/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/50, 0/50, 2/50, 2/50 | Neoplastic Lesions |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Some Evidence | Some Evidence | adenoma 1/49, 0/50, 3/49, 1/49; follicular cell, carcinoma 0/49, 0/50, 1/49, 1/49 | Neoplastic Lesions |
| No | TR-578 | 90045-36-6 | Ginkgo biloba extract | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Some Evidence | Some Evidence | adenoma 2/50, 1/50, 3/49, 5/45 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | All Organs | Clear Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48 | May Have Been Related |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 4/48 6/48 7/48 11/48 14/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/45 3/48 10/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/48 3/48 10/47 17/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 1/45 1/45 1/47 5/45 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/48 1/48 0/48 0/47 3/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/45 19/47 20/47 24/46 40/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 3/47 17/47 23/47 32/46 42/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant schwannoma 2/48 3/48 3/48 7/47 8/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 26/48 35/48 33/48 36/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Equivocal Evidence | granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/47 3/48 6/47 13/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46 | Neoplastic Lesions |
| Yes | TR-563 | 89-82-7 | Pulegone | Mice | B6C3F1/N | Female | Gavage | All Organs | Clear Evidence | Equivocal Evidence | Osteoma or osteosarcoma: 0/49 0/50 3/50 1/50 | May Have Been Related |
| No | TR-563 | 89-82-7 | Pulegone | Mice | B6C3F1/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | Hepatocellular: Adenoma 13/49 15/50 13/50 27/50 adenoma, carcinoma or hepatoblastoma 17/49 15/50 15/50 33/50 | Neoplastic Lesions |
| No | TR-563 | 89-82-7 | Pulegone | Mice | B6C3F1/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | Hepatocellular: Adenoma 22/50 31/50 35/50 28/50 adenoma, carcinoma, or hepatoblastoma 29/50 37/50 42/50 36/50 | Neoplastic Lesions |
| No | TR-563 | 89-82-7 | Pulegone | Rats | F344/N | Female | Gavage | Urinary Bladder | Some Evidence | Some Evidence | Papilloma 0/50 0/49 1/50 3/47 papilloma or carcinoma 0/50 0/49 1/50 5/47 | Neoplastic Lesions |
| Yes | TR-587 | 79-94-7 | Tetrabromobisphenol A | Mice | B6C3F1/N | Male | Gavage | All Organs | Some Evidence | Equivocal Evidence | (Hemangiosarcoma) 1/50 5/50 8/50 | May Have Been Related |
| No | TR-587 | 79-94-7 | Tetrabromobisphenol A | Mice | B6C3F1/N | Male | Gavage | Intestines (Large) | Some Evidence | Equivocal Evidence | (cecum or colon) adenoma or carcinoma 0/50 0/50 3/50 | May Have Been Related |
| No | TR-587 | 79-94-7 | Tetrabromobisphenol A | Mice | B6C3F1/N | Male | Gavage | Liver | Some Evidence | Some Evidence | hepatoblastoma 2/50 11/50 8/50 | Neoplastic Lesions |
| No | TR-587 | 79-94-7 | Tetrabromobisphenol A | Rats | Wistar Han | Male | Gavage | Testis | Equivocal Evidence | Equivocal Evidence | interstitial cell, adenoma 0/50 0/50 1/50 3/50 | May Have Been Related |
| No | TR-587 | 79-94-7 | Tetrabromobisphenol A | Rats | Wistar Han | Female | Gavage | Uterus | Clear Evidence | Clear Evidence | adenoma (original transverse review) 0/50 0/50 3/50 4/50 adenocarcinoma (original transverse review) 3/50 3/50 8/50 9/50 )original transverse and residual longitudinal reviews, combined) 4/50 10/50 15/50 16/50 malignant mixed Müllerian tumor (original transverse review) 0/50 4/50 0/50 2/50 adenoma, adenocarcinoma, or malignant mixed Müllerian tumor (original transverse review) 3/50 7/50 11/50 13/50 )original transverse and residual longitudinal reviews, combined) 6/50 11/50 16/50 19/50 | Neoplastic Lesions |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | All Organs | Some Evidence | Equivocal Evidence | malignant mesothelioma 0/50 1/50 1/50 0/50 | May Have Been Related |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | hemangioma or hemangiosarcoma 4/50 6/50 6/50 11/50 | Neoplastic Lesions |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 28/50 23/50 | Neoplastic Lesions |
| Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | All Organs | Some Evidence | Some Evidence | mononuclear cell leukemia 10/50 11/50 13/50 25/50 | Neoplastic Lesions |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | (Duodenum, Jejunum, or Ileum): carcinoma 1/50 1/50 1/50 3/50 | May Have Been Related |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Male | Inhalation | Kidney | Clear Evidence | Clear Evidence | renal tubule adenoma 0/50 5/50 19/50 10/50 renal tubule carcinoma 0/50 7/50 31/50 18/50 renal tubule adenoma or carcinoma 0/50 11/50 37/50 27/50 | Neoplastic Lesions |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | Kidney | Clear Evidence | Clear Evidence | renal tubule carcinoma 0/50 2/50 1/49 1/50 | Neoplastic Lesions |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Male | Inhalation | Liver | Clear Evidence | Equivocal Evidence | hepatocholangiocarcionoma 1/50 2/50 2/50 3/50 | May Have Been Related |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma 25/50 21/50 36/50 29/50 hepatocellular carcinoma 8/50 14/50 12/50 17/50 hepatocellular adenoma or carcinoma 28/50 30/50 37/50 38/50 hepatocholangiocarcinoma 0/50 1/50 1/50 2/50 | Neoplastic Lesions |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Lung | Clear Evidence | Equivocal Evidence | alveolar/bronchiolar carcinoma 1/50 2/50 7/50 5/49 | May Have Been Related |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | Nasal Cavity | Clear Evidence | Clear Evidence | respiratory epithelium, adenoma 0/49 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | Thyroid Gland C-Cell | Some Evidence | Some Evidence | adenoma 3/50 4/50 6/48 11/50; carcinoma 0/50 6/50 2/48 2/50 adenoma or carcinoma 3/50 10/50 8/48 13/50 | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 18/50 37/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 3/50 1/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 4/50 3/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 6/50 11/50 14/49 19/51 adenoma or carcinoma 6/50 11/50 14/49 20/51 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma 33/49 42/50 42/49 44/50 hepatocellular carcinoma 9/49 17/50 22/49 26/50 hepatoblastoma 0/49 1/50 4/49 6/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 36/49 44/50 43/49 46/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | hepatocellular carcinoma 12/50 22/50 27/49 39/51 hepatoblastoma 4/50 24/50 40/49 34/51 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 28/50 47/50 47/50 39/50 carcinoma 0/50 1/50 3/50 8/50 fibroadenoma, adenoma, or carcinoma 28/50 47/50 48/50 42/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | (oral mucosa and tongue): squamous cell papilloma or squamous cell carcinoma 1/50 0/50 3/50 3/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (subcutaneous tissue): fibroma 4/50 6/50 10/50 15/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma, keratoacanthoma, sebaceous gland adenoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma 9/50 7/50 15/50 21/50 | Neoplastic Lesions |